Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
World J Gastroenterol ; 26(17): 2064-2081, 2020 May 07.
Article in English | MEDLINE | ID: mdl-32536775

ABSTRACT

BACKGROUND: Epigallocatechin gallate (EGCG) is a polyhydroxy phenolic compound extracted from tea and its antitumor effect has received widespread attention. We explored the inhibitory effect of EGCG on dimethylhydrazine (DMH)-induced colorectal cancer (CRC) using a rat model, predicted the interaction between EGCG and CRC target genes using a database, and explained the EGCG associated target pathways and mechanisms in CRC. AIM: To understand the inhibitory mechanisms of EGCG on CRC cell proliferation and identify its pharmacological targets by network pharmacology analysis. METHODS: DMH (40 mg/kg, s.c., twice weekly for eight weeks) was used to induce CRC in rats. After model establishment, the rats were administered with EGCG (50, 100, or 200 mg/kg, p.o., once daily for eight weeks) and killed 12 and 20 wk after the start of the experiment. Formation of aberrant crypt foci and tumor was studied by histological analysis. Using network pharmacology analysis, candidate and collective targets of EGCG and CRC were identified, and Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analyses were used to predict the pathways altered by EGCG. RESULTS: At week 12, high-dose EGCG treatment significantly reduced the tumor formation rate, total number of tumors, cancerous and non-cancerous tumors, tumor volume, ascites formation, and aberrant crypt foci count. At week 20, all three doses of EGCG were effective. Seventy-eight collective targets of EGCG and CRC were identified, of which 28 genes were dysregulated in CRC. Kyoto Encyclopedia of Genes and Genomes and GO analyses showed that the dysregulated genes were enriched in hsa05210 (CRC), hsa04115 (p53 signaling pathway), and hsa04151 (PI3K-Akt signaling pathway), GO:0043124 (negative regulation of I-kappaB kinase/NF-kappaB signaling pathway), GO:0043409 (negative regulation of mitogen-activated protein kinase cascade), and GO:2001244 (positive regulation of intrinsic apoptotic signaling pathway) respectively. CONCLUSION: EGCG inhibits the formation of DMH-induced CRC by regulating key pathways involved in tumorigenesis.


Subject(s)
Aberrant Crypt Foci/prevention & control , Anticarcinogenic Agents/pharmacology , Catechin/analogs & derivatives , Colorectal Neoplasms/prevention & control , Neoplasms, Experimental/prevention & control , Aberrant Crypt Foci/chemically induced , Aberrant Crypt Foci/genetics , Aberrant Crypt Foci/pathology , Animals , Anticarcinogenic Agents/therapeutic use , Carcinogenesis/drug effects , Carcinogenesis/genetics , Catechin/pharmacology , Catechin/therapeutic use , Cell Proliferation/drug effects , Cell Proliferation/genetics , Colon/drug effects , Colon/pathology , Colorectal Neoplasms/chemically induced , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Dimethylhydrazines/toxicity , Gene Expression Regulation, Neoplastic/drug effects , Gene Regulatory Networks/drug effects , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Male , Neoplasms, Experimental/chemically induced , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Protein Interaction Maps/drug effects , Protein Interaction Maps/genetics , Rats , Rectum/drug effects , Rectum/pathology , Signal Transduction/drug effects , Signal Transduction/genetics
2.
Cancer Prev Res (Phila) ; 13(3): 229-240, 2020 03.
Article in English | MEDLINE | ID: mdl-32132117

ABSTRACT

The discovery of aberrant crypt foci (ACF) more than three decades ago not only enhanced our understanding of how colorectal tumors form, but provided new opportunities to detect lesions prior to adenoma development and intervene in the colorectal carcinogenesis process even earlier. Because not all ACF progress to neoplasia, it is important to stratify these lesions based on the presence of dysplasia and establish early detection methods and interventions that specifically target dysplastic ACF (microadenomas). Significant progress has been made in characterizing the morphology and genetics of dysplastic ACF in both preclinical models and humans. Image-based methods have been established and new techniques that utilize bioactivatable probes and capture histologic abnormalities in vivo are emerging for lesion detection. Successful identification of agents that target dysplastic ACF holds great promise for intervening even earlier in the carcinogenesis process to maximize tumor inhibition. Future preclinical and clinical prevention studies should give significant attention to assessing the utility of dysplastic ACF as the earliest identifiable biomarker of colorectal neoplasia and response to therapy.See all articles in this Special Collection Honoring Paul F. Engstrom, MD, Champion of Cancer Prevention.


Subject(s)
Aberrant Crypt Foci/therapy , Adenoma/prevention & control , Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/prevention & control , Dietary Supplements , Aberrant Crypt Foci/diagnosis , Aberrant Crypt Foci/genetics , Aberrant Crypt Foci/pathology , Adenoma/pathology , Adenomatous Polyposis Coli Protein/genetics , Animals , Antineoplastic Agents/pharmacology , Aspirin/pharmacology , Aspirin/therapeutic use , Atorvastatin/pharmacology , Atorvastatin/therapeutic use , Carcinogenesis/drug effects , Catechin/administration & dosage , Catechin/analogs & derivatives , Clinical Trials as Topic , Colon/diagnostic imaging , Colon/drug effects , Colon/pathology , Colonoscopy , Colorectal Neoplasms/pathology , Disease Models, Animal , Humans , Intestinal Mucosa/diagnostic imaging , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Lycopene/administration & dosage , Mice , Mutation , Treatment Outcome
3.
Genet Mol Res ; 16(1)2017 Mar 22.
Article in English | MEDLINE | ID: mdl-28340269

ABSTRACT

Colorectal cancer is a global public health issue. Studies have pointed to the protective effect of probiotics on colorectal carcinogenesis. Activia® is a lacto probiotic product that is widely consumed all over the world and its beneficial properties are related, mainly, to the lineage of traditional yoghurt bacteria combined with a specific bacillus, DanRegularis, which gives the product a proven capacity to intestinal regulation in humans. The aim of this study was to evaluate the antigenotoxic, antimutagenic, and anticarcinogenic proprieties of the Activia product, in response to damage caused by 1,2-dimethylhydrazine (DMH) in Swiss mice. Activia does not have shown antigenotoxic activity. However, the percent of DNA damage reduction, evaluated by the antimutagenicity assay, ranged from 69.23 to 96.15% indicating effective chemopreventive action. Activia reduced up to 79.82% the induction of aberrant crypt foci by DMH. Facing the results, it is inferred that Activia facilitates the weight loss, prevents DNA damage and pre-cancerous lesions in the intestinal mucosa.


Subject(s)
Aberrant Crypt Foci/prevention & control , Anticarcinogenic Agents/pharmacology , Colorectal Neoplasms/prevention & control , DNA Damage , Probiotics/pharmacology , Yogurt/microbiology , 1,2-Dimethylhydrazine , Aberrant Crypt Foci/chemically induced , Aberrant Crypt Foci/genetics , Aberrant Crypt Foci/pathology , Animals , Colorectal Neoplasms/chemically induced , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Dietary Supplements , Intestinal Mucosa/drug effects , Intestinal Mucosa/pathology , Male , Mice
4.
BMC Complement Altern Med ; 15(1): 419, 2015 Nov 25.
Article in English | MEDLINE | ID: mdl-26608653

ABSTRACT

BACKGROUND: With cancer being one of the major causes of death around the world, studies are ongoing to find new chemotherapeutic leads. There are common mechanisms for colorectal cancer (CRC) formation. Several are connected with oxidative stress-induced cell apoptosis and others are related to imbalanced homeostasis or intake of drugs/toxins. Plants that have been used for decades in folk and traditional medicine have been accepted as one of the commonest sources of discovered natural agents of cancer chemotherapy and chemoprevention. The aim was to study the antioxidant and chemopreventive effects of Strobilanthes crispus on colorectal cancer formation. METHODS: Five groups of rats were injected subcutaneously with AOM, 15 mg/kg body weight, each once weekly for 2 weeks. The cancer group was continued on 10 % Tween-20 feeding for 8 weeks. The standard drug group was continued on 35 mg/kg 5-fluorouracil intraperitoneal injection twice a week for 8 weeks, and the experimental groups were continued on 250 and 500 mg/kg S. crispus extract oral feeding for 8 weeks, respectively. The normal group was injected subcutaneously with normal saline once a week for 2 weeks, followed by oral administration of 10 % Tween-20 for 8 weeks. All the rats were sacrificed after 10 weeks. The colons were evaluated grossly and histopathologically for aberrant crypt foci (ACF). Gene expression was performed for Bax, Bcl2, Defa24, Slc24a3, and APC genes by real-time PCR. S. crispus and its fractions were evaluated for their chemopreventive effects against human colorectal adenocarcinoma cell line HT29 and cytotoxicity for normal human colon epithelial cell line CCD 841, and the active fraction was assessed for its components. RESULTS: We observed significant decrease in total colonic ACF formation, malonaldehyde (MDA) and lactate dehydrogenase (LDH), increase in superoxide dismutase (SOD), up-regulation of APC, Bax and Slc24a3, and down-regulation of Defa24 and Bcl-2 in rats treated with Strobilanthes crispus. CONCLUSION: Our results support the in vivo protection of S. crispus against CRC formation (azoxymethane-induced aberrant crypt foci) and suggest that the mechanism is highly specific to protect from oxidative insults and the following apoptotic cascade.


Subject(s)
Aberrant Crypt Foci/drug therapy , Acanthaceae , Adenocarcinoma/drug therapy , Anticarcinogenic Agents/pharmacology , Colonic Neoplasms/drug therapy , Phytotherapy , Aberrant Crypt Foci/genetics , Aberrant Crypt Foci/pathology , Acanthaceae/chemistry , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Animals , Anticarcinogenic Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Apoptosis/drug effects , Cell Line, Tumor/drug effects , Chemoprevention , Colonic Neoplasms/genetics , Colonic Neoplasms/pathology , Humans , Male , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Rats , Rats, Sprague-Dawley
5.
Asian Pac J Cancer Prev ; 16(3): 947-52, 2015.
Article in English | MEDLINE | ID: mdl-25735387

ABSTRACT

UNLABELLED: The aim of this study was to evaluate the effects of grape juice on colon carcinogenesis induced by azoxymethane (AOM) and expression of NF-kB, iNOS and TNF- α. METHODS: Forty male Wistar rats were divided into 7 groups: G1, control; G2, 15 mg/kg AOM; G3, 1% grape juice 2 weeks before AOM; G4, 2% grape juice 2 weeks before AOM; G5, 1% grape juice 4 weeks after AOM; G6, 2% grape juice 4 weeks after AOM; G7, 2% grape juice without AOM. Histological changes and aberrant crypt foci (ACF) were studied, while RNA expression of NF- kB, TNF- and iNOS was evaluated by qPCR. RESULTS: The number of ACF was higher in G2, and G4 presented a smaller number of crypts per focus than G5 (p=0.009) and G6. Small ACF (1-3) were more frequent in G4 compared to G2, G5 and G6 (p=0.009, p=0.009 and p=0.041, respectively). RNA expression of NF-kB was lower in G3 and G4 compared to G2 (p=0.004 and p=0.002, respectively). A positive correlation was observed between TNF- α and NF-kB gene expression (p=0.002). In conclusion, the administration of 2% grape juice before AOM reduced the crypt multiplicity, attenuating carcinogenesis. Lower expression of NF-kB was observed in animals exposed to grape juice for a longer period of time, regardless of concentration.


Subject(s)
Aberrant Crypt Foci/drug therapy , Colorectal Neoplasms/drug therapy , Cyclooxygenase 2/genetics , Gene Expression Regulation, Neoplastic/drug effects , NF-kappa B/genetics , Tumor Necrosis Factor-alpha/genetics , Vitis/chemistry , Aberrant Crypt Foci/chemically induced , Aberrant Crypt Foci/genetics , Aberrant Crypt Foci/pathology , Animals , Apoptosis/drug effects , Azoxymethane/toxicity , Carcinogens/toxicity , Cell Proliferation/drug effects , Colorectal Neoplasms/chemically induced , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Humans , Male , Phytotherapy , Plant Extracts , Precancerous Conditions/chemically induced , Precancerous Conditions/drug therapy , Precancerous Conditions/genetics , Precancerous Conditions/pathology , RNA, Messenger/genetics , Rats , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tumor Cells, Cultured
6.
Mol Nutr Food Res ; 56(4): 641-52, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22495988

ABSTRACT

SCOPE: Previous studies have shown that vitamin B6 supplementation suppresses the development of colonic aberrant crypt foci (ACF), precursor lesions of colon cancer, and cell proliferation in mice receiving the colonic carcinogen, azoxymethane (AOM). This study investigated the molecular mechanism of these effects of dietary vitamin B6. METHODS AND RESULTS: To date, the mechanism by which ACFs develop is not yet fully understood. In a search for factors that play a critical role during ACF development, we examined colon gene expression during early stage of ACF development in AOM-treated mice using DNA microarray analysis. AOM treatment significantly upregulated mRNA closely related to mast cell and cytotoxic T-cell activity. This study also investigated the effect of vitamin B6 supplementation on colon gene expression in AOM-treated mice. We found that vitamin B6 supplementation downregulates Cd8a and Ccl8 mRNA expression, suggesting these candidate genes may play a protective role against colonic ACF development. Furthermore, we examined genomic affects of dietary vitamin B6, and showed that Reg3γ mRNA expression in colons is downregulated by vitamin B6. CONCLUSION: This study provides an insight into the genomic activities of dietary vitamin B6 that may be protective against colon tumor development.


Subject(s)
Aberrant Crypt Foci/genetics , Colon/drug effects , Colonic Neoplasms/genetics , Dietary Supplements , Gene Expression Regulation, Neoplastic , Vitamin B 6/administration & dosage , Aberrant Crypt Foci/pathology , Aberrant Crypt Foci/prevention & control , Animals , Azoxymethane/toxicity , CD8 Antigens/genetics , CD8 Antigens/metabolism , Cell Proliferation/drug effects , Chemokine CCL8/genetics , Chemokine CCL8/metabolism , Colon/metabolism , Colon/pathology , Colonic Neoplasms/pathology , Colonic Neoplasms/prevention & control , Down-Regulation , Male , Mice , Mice, Inbred ICR , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL